Ocuphire Pharma Announces Upcoming Presentations at Two Conferences in August
Canaccord Genuity 42nd Annual Growth Conference on August 10, 2022 H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference on August 17,...
Clinical Trial
Krystal Biotech Announces Second Quarter 2022 Financial Results and Reports Updates on Operational Progress
Biologics License Application for B-VEC filed with the FDA on June 22, 2022FDA accepts IND on KB407 for the treatment...
PDS Biotech Reports Second Quarter 2022 Financial Results and Provides Business Update
Announced results from two of the ongoing Phase 2 clinical trials of PDS0101 in multiple, difficult-to-treat HPV16-related cancers presented at...
TCR² Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
- gavo-cel Phase 1 trial dataset anticipated in September 2022- Initial TC-510 Phase 1 data anticipated in 2H 2022 -...
Pfizer to Acquire Global Blood Therapeutics for $5.4 Billion to Enhance Presence in Rare Hematology
Proposed acquisition drives growth by bringing leading sickle cell disease expertise, portfolio and pipeline to Pfizer with potential combined worldwide...
Bionomics Receives R&D Tax Incentive Refund for FY2021 of A$2.1M
ADELAIDE, Australia, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX: BNO, NASDAQ:BNOX), a clinical stage biopharmaceutical company, is pleased...
BioNTech Announces Second Quarter Financial Results and Corporate Update
Second quarter revenues of €3.2 billion1, net profit of €1.7 billion and fully diluted earnings per share of €6.45 ($6.872) as well...
Myovant Sciences and Pfizer Receive U.S. FDA Approval of MYFEMBREE®, a Once-Daily Treatment for the Management of Moderate to Severe Pain Associated With Endometriosis
Data from the Phase 3 SPIRIT program showed MYFEMBREE reduced menstrual pain and non-menstrual pelvic pain in premenopausal women with...
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
MALVERN, Pa., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on...
Todos Medical Announces First Long COVID Clinic Laboratory Services Agreement for Long COVID Panel Biomarker Partnership with Amerimmune Diagnostics
RTHM collaborating on Tollovid™ 3CL inhibitor immune support supplement case studiesTollovid biomarker data to support potential structure-function claims in Long...
Tarsus Initiates Phase 2a Ersa Trial Evaluating TP-03 for the Treatment of Meibomian Gland Disease
IRVINE, Calif., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet...
Humacyte to Present Second Quarter 2022 Financial Results and Provide Recent Corporate Update on August 12, 2022
DURHAM, N.C., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable...
Panbela Expands Aspire Trial to Australia, Studying SBP-101 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
MINNEAPOLIS, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for...
Salarius Pharmaceuticals Adds Seattle Cancer Care Alliance and Oregon Health & Sciences as Clinical Sites for its Ongoing Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas
Clinical Trial Now Expands to Fifteen U.S. Trial SitesHOUSTON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX),...
Vaxcyte Provides Positive Regulatory Updates for VAX-24 Adult and Pediatric Programs
-- Company Receives FDA Fast Track Designation for VAX-24 in Adults -- -- Vaxcyte Completes Successful Pre-IND Meeting with FDA...
SCYNEXIS Presents Positive Data from Its Pivotal Phase 3 CANDLE Study of Oral Ibrexafungerp for Prevention of Recurrent Vaginal Yeast Infections During the 2022 IDSOG Annual Meeting
The CANDLE study met its primary endpoint, with 65.4% of patients with recurrent vulvovaginal candidiasis (RVCC) who received monthly single-day...
Madrigal Pharmaceuticals Provides Clinical and Business Updates and Reports 2022 Second Quarter Financial Results
Madrigal remains on track to announce topline data from the Phase 3 MAESTRO-NASH biopsy study in the fourth quarterCONSHOHOCKEN, Pa.,...
C4 Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights
– CFT7455, a Novel IKZF1/3 Degrader, Advancing Through Dose Escalation Portion of Phase 1/2 Clinical Trial – – Phase 1/2 Clinical...
Noema Pharma Announces Recruitment of First Patient in Orpheus Phase 2b Study of PDE10A Inhibitor gemlapodect in Adults with Childhood Onset Fluency Disorder
Study evaluating the safety and efficacy of gemlapodect (NOE-105) in adults with Childhood Onset Fluency Disorder (also known as stuttering)Top-line...
Magenta Therapeutics Reports Second Quarter Financial Results and Recent Program Highlights
– MGTA-117 Phase 1/2 clinical trial progress continues and remains consistent with earlier observations of target binding, target cell reductions,...